Teva Pharmaceutical meets forecasts, but 2023 outlook disappoints | Reuters
A massive lawsuit just erased $2.5 billion from drug giant Teva's market cap. Here's how much Teva and rival drugmaker Mylan could stand to lose in court. | Business Insider India